Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity.

Kolotkin RL, Gabriel Smolarz B, Meincke HH, Fujioka K

Clinical obesity16 Oct 2017Cited by 32 (Europe PMC)

PMID29045079PMCIDPMC5813214DOI10.1111/cob.12226PepBankPUB-29045079

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, liraglutide 3.0 mg improved the IWQOL-Lite total score more than placebo at 3 years (estimated treatment difference 3.4).
In plain wordsIn adults with overweight or obesity, liraglutide improved weight-related quality of life more than placebo over 3 years.
Peptide
Liraglutide
Outcome
IncreaseIWQOL-Lite total score change at 3 years
Study
n = 2,210
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
3.0 mg · 3 yearsAs given in this study (human).
Measurements
IWQOL-Lite estimated treatment difference
3.4 points
liraglutide vs placebo
Source sentences
Summary
At 3 years, mean change (±standard deviation) in IWQOL-Lite total score from baseline for liraglutide (n = 1472) was 11.0 ± 14.2, vs. 8.1 ± 14.7 for placebo (n = 738) (estimated treatment difference [ETD] 3.4 [95% confidence interval (CI): 2.0, 4.7], P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Previously in the SCALE Obesity and Prediabetes trial, at 1 year, participants with obesity (or overweight with comorbidities) and prediabetes receiving liraglutide 3.0 mg experienced greater improvements in health-related quality of life (HRQoL) than those receiving placebo.
Report a problemFND-2904507901
02HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, liraglutide 3.0 mg improved the SF-36 physical component summary score more than placebo (estimated treatment difference 0.87).
In plain wordsIn adults with overweight or obesity, liraglutide improved physical health scores slightly more than placebo.
Peptide
Liraglutide
Outcome
IncreaseSF-36 physical component summary score change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
3.0 mg · 3 yearsAs given in this study (human).
Measurements
SF-36 PCS estimated treatment difference
0.87 points
liraglutide vs placebo
Source sentences
Summary
Mean change in SF-36 physical component summary (PCS) score from baseline for liraglutide was 3.1 ± 7.3, vs. 2.6 ± 7.6 for placebo (ETD 0.87 [95% CI: 0.17, 1.6], P = 0.0156).
1 context sentence(design, population, supporting numbers)
Summary · context
Previously in the SCALE Obesity and Prediabetes trial, at 1 year, participants with obesity (or overweight with comorbidities) and prediabetes receiving liraglutide 3.0 mg experienced greater improvements in health-related quality of life (HRQoL) than those receiving placebo.
Report a problemFND-2904507902
03HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, the SF-36 mental component summary score change did not differ significantly between liraglutide 3.0 mg and placebo.
In plain wordsIn adults with overweight or obesity, liraglutide and placebo did not differ in mental health scores.
Peptide
Liraglutide
Outcome
No significant changeSF-36 mental component summary score change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
3.0 mg · 3 yearsAs given in this study (human).
Source sentences
Summary
Mean change in SF-36 mental component summary score did not significantly differ between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Previously in the SCALE Obesity and Prediabetes trial, at 1 year, participants with obesity (or overweight with comorbidities) and prediabetes receiving liraglutide 3.0 mg experienced greater improvements in health-related quality of life (HRQoL) than those receiving placebo.
Report a problemFND-2904507903
04HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, liraglutide 3.0 mg was associated with improved health utility compared with placebo.
In plain wordsIn adults with overweight or obesity, liraglutide was linked to better health utility scores than placebo.
Peptide
Liraglutide
Outcome
IncreaseHealth utility (SF-6D and EQ-5D)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
3.0 mg · 3 yearsAs given in this study (human).
Source sentences
Summary
Liraglutide 3.0 mg was also associated with improved health utility (Short-Form-6D and EuroQol-5D, mapped from IWQOL-Lite and/or SF-36) vs. placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Previously in the SCALE Obesity and Prediabetes trial, at 1 year, participants with obesity (or overweight with comorbidities) and prediabetes receiving liraglutide 3.0 mg experienced greater improvements in health-related quality of life (HRQoL) than those receiving placebo.
Report a problemFND-2904507904

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

05HumanNot a test of Liraglutide aloneRandomized controlled trialOther
In adults with overweight or obesity, greater improvement in IWQOL-Lite total score and physical component score was associated with higher weight loss.
In plain wordsIn adults with overweight or obesity, more weight loss was linked to bigger quality-of-life gains.
Peptide
Liraglutide
Outcome
Not applicableAssociation of HRQoL improvement with weight loss
Study
n: not reported in source
Outcome group
Quality of life · Whole body
Source sentences
Summary
Both IWQOL-Lite total score and PCS score demonstrated an association between greater HRQoL improvement with higher weight loss.
1 context sentence(design, population, supporting numbers)
Summary · context
Previously in the SCALE Obesity and Prediabetes trial, at 1 year, participants with obesity (or overweight with comorbidities) and prediabetes receiving liraglutide 3.0 mg experienced greater improvements in health-related quality of life (HRQoL) than those receiving placebo.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2904507905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01272219

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Novo Nordisk A/Sn = 3,7311 Jun 2011 to 2 Mar 2015

Metabolism and Nutrition Disorder · Obesity

Trial page ClinicalTrials.govUpdated 19 Jan 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.